Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a 7% revenue growth and a 10% increase in adjusted EPS, showcasing strong financial performance. Despite a slight decline in gross margin, the overall financial health appears robust with improved cash flow and operating income. The raised guidance for fiscal 2026 further supports a positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term, as the financial metrics and optimistic guidance outweigh any minor concerns.
Key Financial Performance
Revenue Cencora reported a revenue of $62.5 billion for Q2 2026, representing a 7% increase year-over-year. The growth was driven by strong performance in the pharmaceutical distribution segment and increased demand for specialty products.
Operating Income The operating income for Q2 2026 was $1.2 billion, up 5% year-over-year. This increase was attributed to improved operational efficiencies and cost management initiatives.
Earnings Per Share (EPS) Adjusted EPS for Q2 2026 was $3.45, reflecting a 10% growth compared to the same period last year. The rise was due to higher revenue and effective cost control measures.
Gross Margin Gross margin for the quarter was 5.8%, a slight decrease from 6.0% in Q2 2025. The decline was primarily due to changes in product mix and pricing pressures in certain segments.
Cash Flow from Operations Cash flow from operations stood at $1.5 billion for Q2 2026, marking a 12% increase year-over-year. This improvement was driven by better working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allen Lutz
BofA Securities
CFO Gill
Cencora Inc
Director Cleary
Division Allen
Division Anderson
Division Cherny
Division EDT
Division Eric
Division Erin
Division George
Division Glen
Division Kevin
EDT Hello
Enterprise Productivity
Eric Percher
Erin Wilson
George Hill
Glen Santangelo
Hello Cencora
Inc today
Instructions conference
Kevin Caliendo
LLC Rhyee
Lutz BofA
Relations Enterprise
Research Division
Santangelo Barclays
Securities Research
Treasury Mauch
VP
answer session
conference Senior
remark answer
COR Transcript
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a 7% revenue growth and a 10% increase in adjusted EPS, showcasing strong financial performance. Despite a slight decline in gross margin, the overall financial health appears robust with improved cash flow and operating income. The raised guidance for fiscal 2026 further supports a positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term, as the financial metrics and optimistic guidance outweigh any minor concerns.
Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
Positive2-4
The earnings call reflects a positive outlook with increased guidance for operating income and EPS, strategic partnerships, and strong specialty sales. Despite some headwinds like the oncology customer loss and interest expenses, the company anticipates growth driven by the OneOncology acquisition and strategic investments. The Q&A section reassures that challenges like the International segment timing issue won't affect full-year guidance. Additionally, a 9% dividend increase aligns with EPS growth guidance, further supporting a positive sentiment.
COR Slides
COR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
